Galenica AG (SWX:GALE)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 4.16B -4.7% |
| Revenue (ttm) | 4.15B +5.5% |
| Net Income | 181.10M -1.0% |
| EPS | 3.63 -1.1% |
| Shares Out | 49.82M |
| PE Ratio | 22.79 |
| Forward PE | 20.95 |
| Dividend | 2.50 (3.00%) |
| Ex-Dividend Date | Apr 23, 2026 |
| Volume | 112,376 |
| Average Volume | 97,955 |
| Open | 83.60 |
| Previous Close | 82.90 |
| Day's Range | 82.60 - 83.70 |
| 52-Week Range | 81.10 - 103.00 |
| Beta | 0.28 |
| RSI | 41.51 |
| Earnings Date | Aug 6, 2026 |
About Galenica AG
Galenica AG provides healthcare services in Switzerland and internationally. It operates through two segments, Products & Care, and Logistics & IT. The Products & Care segment operates and manages pharmacies and partner pharmacies under the Amavita, Sun Store, and Coop Vitality brands, as well as covers specialty pharmacy mediservice. This segment also offers medication for treatment of patients at home; laboratory medicine, pathology and specialized personalized diagnostic services; and develops, markets, and sells healthcare services and prod... [Read more]
Financial Performance
In 2025, Galenica AG's revenue was 4.15 billion, an increase of 5.48% compared to the previous year's 3.93 billion. Earnings were 181.10 million, a decrease of -1.01%.
Financial StatementsNews
Galenica AG Earnings Call Transcript: H2 2025
Group sales grew 5.5% in 2025, with EBIT up 11.3% and strong cash flow supporting a 20% dividend increase. Strategic acquisitions, digital expansion, and efficiency gains drive positive 2026 guidance, despite ongoing price pressure and ERP transition delays.
Galenica AG Quarterly report: H2 2025
Galenica AG has published its H2 2025 quarterly earnings report on March 10, 2026.
Galenica AG Annual report: H2 2025
Galenica AG has published its H2 2025 annual report on March 10, 2026.
Galenica AG Slides: H2 2025
Galenica AG has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 10, 2026.
Galenica AG Earnings Call Transcript: H2 2025
Strong sales and EBIT growth in 2025 were driven by organic expansion, acquisitions, and efficiency gains, with a positive outlook for 2026 and beyond. Strategic milestones included the Labor Team acquisition, ERP upgrades, and a focus on profitable segments.
Galenica AG Quarterly report: H2 2025
Galenica AG has published its H2 2025 quarterly earnings report on March 10, 2026.
Galenica AG Annual report: H2 2025
Galenica AG has published its H2 2025 annual report on March 10, 2026.
Galenica AG Slides: H2 2025
Galenica AG has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 10, 2026.
Galenica AG Slides: Investor presentation
Galenica AG has posted slides in relation to its latest quarterly earnings report, which was published on March 10, 2026.
Galenica AG Slides: Investor presentation
Galenica AG has posted slides in relation to its latest quarterly earnings report, which was published on March 10, 2026.
Galenica AG Earnings release: Q4 2025
Galenica AG released its Q4 2025 earnings on January 22, 2026, summarizing the period's financial results.
Galenica AG Slides: Q4 2025
Galenica AG has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on January 22, 2026.
Galenica AG Earnings release: Q4 2025
Galenica AG released its Q4 2025 earnings on January 22, 2026, summarizing the period's financial results.
Galenica AG Slides: Q4 2025
Galenica AG has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on January 22, 2026.
Galenica AG Transcript: Investor Day 2025
Transformation is driven by culture, digitalization, and staff engagement, with major investments in logistics, diagnostics, and omni-channel pharmacy services. Growth is targeted through innovation, acquisitions, and efficiency, while regulatory changes and market trends are actively managed.
Galenica AG Slides: FY 2025
Galenica AG has posted slides in relation to its FY 2025 quarterly earnings report, which was published on October 28, 2025.
Galenica AG Transcript: Investor Day 2025
Transformation is driven by culture, digitalization, and staff engagement, with major investments in logistics, diagnostics, and omni-channel pharmacy services. Growth is targeted through innovation, acquisitions, and efficiency, while regulatory changes and market trends are actively managed.
Galenica AG Slides: FY 2025
Galenica AG has posted slides in relation to its FY 2025 quarterly earnings report, which was published on October 28, 2025.
Galenica AG Earnings release: Q3 2025
Galenica AG released its Q3 2025 earnings on October 23, 2025, summarizing the period's financial results.
Galenica AG Slides: Q3 2025
Galenica AG has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 23, 2025.
Galenica AG Earnings release: Q3 2025
Galenica AG released its Q3 2025 earnings on October 23, 2025, summarizing the period's financial results.
Galenica AG Slides: Q3 2025
Galenica AG has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 23, 2025.
Galenica AG Earnings Call Transcript: H1 2025
Sales grew 5% in H1 2025, with improved profitability and cash flow. Guidance for 2025 is confirmed, with EBIT growth outlook raised to 7%-9% due to one-off effects. The acquisition of Labora Team expands into diagnostics, while market and regulatory pressures remain.
Galenica AG Quarterly report: H1 2025
Galenica AG has published its H1 2025 quarterly earnings report on August 7, 2025.
Galenica AG Slides: H1 2025
Galenica AG has posted slides in relation to its H1 2025 quarterly earnings report, which was published on August 7, 2025.